combination therapy with glp-1 receptor agonist and sglt2 inhibitor Blood pressure effects of inhibitors GLP‐1 agonists: Mechanisms, trial evidence and Real‐world data - Belančić - British Journal of Clinical Pharmacology GLP1 Receptor Agonists vs SGLT2-I
Description
doi: 10.1016/j.metabol.2019.154045
doi: 10.1056/NEJMoa2032183
In 1993, Nauck et al
GLP-1s have demonstrated anti-fibrotic properties in other organs (liver, kidney, heart) by reducing collagen deposition and tissue scarring (10)
The potent and reliable metabolic effects, coupled with ease of administration, make Ozempic the leading GLP-1 product globally, capturing the largest market share
